IMPACT of a Diabetes Disease Management Program on Quality of Care and Costs: Propensity Score-Matched Real-World DATA from Switzerland
Author(s)
Carlander M1, Höglinger M1, Trottmann M2, Rhomberg B2, Caviglia C3, Rohrbasser A4, Frei C2, Eichler K1
1Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, Switzerland, 2SWICA, Winterthur, Switzerland, 3Medbase, Winterthur, Switzerland, 4Medbase, Wil, Switzerland
OBJECTIVES Structured treatment programs have been recommended for management of patients with chronic conditions to overcome ill-coordinated care. We aimed to evaluate a disease management program (DMP) for diabetes mellitus patients in Switzerland. METHODS We performed a prospective observational study with a propensity score-matched usual care control group from a claims database. We included type-1 and type-2 diabetes patients from a primary care setting. The DMP (intervention) comprised a structured treatment approach with an individual treatment plan, treatment goals and an interprofessional team approach. Our comprehensive outcome measures included quality of life (QOL: EQ-5D-5L), pre-defined indicators for diabetes guideline adherence, number of used services and direct medical costs. We applied a difference-in-difference (DID) approach to compare DMP with usual care (follow-up 1 year). Costs were calculated with non-parametric bootstrapping (2017 Swiss Francs, CHF; conversion rate to Euros: 0.85) from a third-party payer perspective (Swiss health care insurance). RESULTS QOL in a sub-sample of 80 patients did not change during follow-up (mean utility 0.89 at baseline and follow-up; p=0.94). Guideline adherence showed slight improvements for DMP. For example, “non-adherence” (baseline DMP: 19%) decreased in the DMP group by -3 %-points (DID; 95%-CI: -0.07 to 0.01) but not in the control group. A general trend emerged, though mostly not statistically significant, with less used services in the DMP group compared to the control group. Costs increased in both groups during follow-up, but the increase was higher in the control group (DID, mean total costs per patient per year: CHF -950.00 [95%-CI: -1959.53 to 59.56]). Such a negative difference-in-difference estimate in favor of DMP also emerged for cost sub-categories (e.g. costs for inpatient and outpatient care). CONCLUSIONS The structured treatment program under evaluation is a promising approach to improve diabetes care in a Swiss primary care setting but more follow-up data are needed.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PDB61
Topic
Economic Evaluation, Health Service Delivery & Process of Care, Patient-Centered Research, Real World Data & Information Systems
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis, Health & Insurance Records Systems, Patient-reported Outcomes & Quality of Life Outcomes, Quality of Care Measurement
Disease
Diabetes/Endocrine/Metabolic Disorders
Explore Related HEOR by Topic